OmniAb outlines royalty strategy and new peptide discovery platform

OmniAb held its first formal Investor and Analyst Day in Emeryville to outline a growth strategy centered on royalty-bearing partnerships and new technology platforms. The company is expanding its capabilities by introducing OmniTides, a platform for peptide discovery, and commercializing its xPloration single-B-cell screening system.

OmniAb reported a robust portfolio consisting of more than 110 active partners and over 125 active programs. The company noted more than $3 billion in contracted potential milestones and an average royalty rate of approximately 3.4% across its portfolio. Partners have committed or are currently spending over $2.4 billion to advance clinical programs derived from OmniAb technology.

Key partner programs highlighted include Johnson & Johnson’s ramantamig for multiple myeloma and Merck KGaA’s precemtabart tocentecan antibody-drug conjugate program. The company expects approximately 19 clinical-trial readouts from partner programs to occur between late 2026 and 2027.